Roflumilast Foam 0.3%

Drug identity checked against registry records

Also recorded as ARQ-154; ARQ-154 0.3%

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic DermatitisNCT04091646ARQTPhase 2Completed2020-08-18Actual
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)NCT05028582ARQTPhase 3Completed2022-06-03Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.